Trastuzumab Exposure during Pregnancy with Invasive Breast Cancer

Joon Won Min; Yun Dan Kang

doi:10.14734/PN.2017.28.04.184

Journal List > Perinatology > v.28(4) > 1071360

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Min and Kang: Trastuzumab Exposure during Pregnancy with Invasive Breast Cancer

Original Article

Perinatology 2017;28(4):184-186.

Published online: 19 January 2017

DOI: https://doi.org/10.14734/PN.2017.28.04.184

Trastuzumab Exposure during Pregnancy with Invasive Breast Cancer

Joon Won Min, MD, PhD¹, Yun Dan Kang, MD, PhD²

¹Departments of Surgery, Dankook University College of Medicine, Cheonan, Korea

²Departments of Obstetrics and Gynecology, Dankook University College of Medicine, Cheonan, Korea

Correspondence to Yun Dan Kang MD, PhD Department of Obstetrics and Gynecology, Dankook University College of Medicine, 119 Dandae-ro, Dongnam-gu, Cheonan 31116, Korea Tel: +82-41-550-3792 Fax: +82-41-556-3878 E-mail: yundan76@dankook.ac.kr

Received 28 July 20175 September 2017 Accepted 9 October 2017

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Trastuzumab is a monoclonal antibody used for the treatment of human epidermal growth factor receptor-2 positive breast cancer. There is a little information in the literature regarding the safe use of trastuzumab in pregnancy, although some reports suggest an increased risk of oligohydramnios. We present a case of woman on trastuzumab therapy for breast cancer who became pregnant and delivered healthy live infant.

Keywords: Breast cancer, Pregnancy, Trastuzumab

REFERENCES

1). Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. [accessed on 20 May, 2017]. Available at. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.

2). National Cancer Information Center. Cancer statistics. [accessed on 20 May, 2017]. Available at. http://www.cancer.go.kr/mbs/cancer/subview.jsp?id=cancer_040102000000.

3). Park EH., Min SY., Kim Z., Yoon CS., Jung KW., Nam SJ, et al. Basic facts of breast cancer in Korea in 2014: The 10-year overall survival progress. J Breast Cancer. 2017. 20:1–11.

4). Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005. 365:1687–717.

5). Bader AA., Schlembach D., Tamussino KF., Pristauz G., Petru E. Anhydram-nios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol. 2007. 8:79–81.

6). Watson WJ. Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet Gynecol. 2005. 105:642–3.

7). US Food and Drug Administration. HERCEPTIN^® (trastuzumab). [accessed on 20 May 2017]. Available at. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf.

8). Peccatori FA., Azim HA Jr., Orecchia R., Hoekstra HJ., Pavlidis N., Kesic V, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013. 24(Suppl 6):vi160–70.

9). Howlader N., Noone AM., Krapcho M., Neyman N., Aminou R., Waldron W, et al. SEER cancer statistics review, 1975-2008. [accessed on 20 May, 2017]. Available at. http://seer.cancer.gov/csr/1975_2008/.

10). Slamon DJ., Clark GM., Wong SG., Levin WJ., Ullrich A., McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2⁄neu oncogene. Science. 1987. 235:177–82.

11). Piccart-Gebhart MJ., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005. 353:1659–72.

12). Valero V., Forbes J., Pegram MD., Pienkowski T., Eiermann W., von Minck-witz G, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol. 2011. 29:149–56.

13). National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Breast cancer, version 2.2017. [accessed on 20 May, 2017]. Available at. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.

14). Zagouri F., Sergentanis TN., Chrysikos D., Papadimitriou CA., Dimopoulos MA., Bartsch R. Trastuzumab administration during pregnancy: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013. 137:349–57.

15). Pant S., Landon MB., Blumenfeld M., Farrar W., Shapiro CL. Treatment of breast cancer with trastuzumab during pregnancy. J Clin Oncol. 2008. 26:1567–9.

16). Azim HA Jr., Metzger-Filho O., de Azambuja E., Loibl S., Focant F., Gresko E, et al. Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). Breast Cancer Res Treat. 2012. 133:387–91.

TOOLS

Similar articles